New antibody drug takes aim at Hard-to-Treat brain cancers
NCT ID NCT05916313
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called BI 764532 in 20 adults with a type of brain tumor (glioma) that has a specific marker called DLL3 and hasn't improved with prior treatment. The drug is designed to link cancer cells to immune cells, helping the body fight the tumor. The main goal is to find a safe dose and see if it can be tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 764532 (Obrixtamig), an antibody-like molecule that links cancer cells and immune T-cells
What this could lead to
If it works, this could point toward a new treatment option for people with advanced glioma that hasn't responded to other therapies.
What could go wrong
This is an early, small Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cantonal Hospital of Aarau
Aarau, CH-5001, Switzerland
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Klinikum der Universität München AÖR
München, 81377, Germany
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Salzburg Cancer Research Institute
Salzburg, 5020, Austria
-
University Hosp. Zurich
Zurich, 8901, Switzerland
-
University Hospital of Lausanne
Lausanne, 1101, Switzerland
-
University of California Irvine
Orange, California, 92868, United States
-
Universitätsklinikum Frankfurt
Frankfurt, 60596, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany